Halozyme Therapeutics to Hold 2006 Fourth Quarter and Year End Conference Call on March 8

SAN DIEGO, March 6  /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will release financial results for the three and twelve months ended December 31, 2006 prior to market open on Thursday, March 8, 2007.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, and David Ramsay, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Thursday, March 8, 2007, to discuss these results and provide a business update.

Individuals interested in participating in the conference call may do so by dialing 888-463-4487 for domestic callers, or 706-679-5355 for international callers.  Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's website at http://www.halozyme.com/.  A replay will be available on Halozyme's website for 30 days.  A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation number 1353453.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets.  The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases.  The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics.  Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for 13 targets.  In addition, the company has received FDA approval for two products: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids.  The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

  Halozyme Contact              Investor Relations Contact
  David A. Ramsay               Don Markley
  Chief Financial Officer       Lippert/Heilshorn & Associates
  [phone]                [phone]
            

DATASOURCE: Halozyme Therapeutics, Inc.



CONTACT: David A. Ramsay, Chief Financial Officer of Halozyme

Therapeutics, Inc., [phone], ; or Investor

Relations, Don Markley of Lippert/Heilshorn & Associates, [phone],

, for Halozyme Therapeutics, Inc.



Web site:  http://www.halozyme.com/ 

Copyright